v3.26.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Operating activities    
Net income $ 6,288 $ 4,707
Adjustments to reconcile net income to net cash provided by/(used in) operating activities:    
Depreciation and amortization 1,151 757
Noncash lease expense 130 104
Stock-based compensation 911 886
Deferred income tax expense (benefit) (229) (238)
Change in fair value of contingent consideration 26 265
Other investment gains (206) (360)
Net (gains) losses within CIPs (382) (419)
Net (purchases) proceeds within CIPs (3,886) (3,344)
(Earnings) losses from equity method investees (180) (48)
Distributions of earnings from equity method investees 172 155
Changes in operating assets and liabilities:    
Accounts receivable (638) (265)
Investments, trading 251 139
Other assets (1,948) (2,666)
Accrued compensation and benefits (405) (391)
Accounts payable and accrued liabilities 230 (21)
Other liabilities 1,668 2,389
Net cash provided by/(used in) operating activities 2,953 1,650
Investing activities    
Purchases of investments (1,214) (1,144)
Proceeds from sales and maturities of investments 341 467
Distributions of capital from equity method investees 175 297
Net consolidations (deconsolidations) of sponsored investment funds (68) (85)
Acquisitions, net of cash acquired (15) (3,496)
Purchases of property and equipment (316) (245)
Net cash provided by/(used in) investing activities (1,097) (4,206)
Financing activities    
Repayments of long-term borrowings 0 (796)
Proceeds from long-term borrowings 0 1,080
Dividends/Subco distributions paid (2,837) (2,497)
Proceeds from stock options exercised 127 153
Shares/Subco Units repurchased (1,839) (1,437)
Net proceeds from (repayments of) borrowings by CIPs 403 (44)
Net subscriptions received/(redemptions/distributions paid) from noncontrolling interest holders 3,802 3,000
Other financing activities (29) 2
Net cash provided by/(used in) financing activities (373) (539)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (74) 317
Net increase/(decrease) in cash, cash equivalents and restricted cash 1,409 (2,778)
Cash, cash equivalents and restricted cash, beginning of period 11,490 12,779
Cash, cash equivalents and restricted cash, end of period 12,899 10,001
Supplemental schedule of noncash investing and financing transactions:    
Issuance of common shares related to employee stock transactions 939 119
Increase (decrease) in noncontrolling interests due to net consolidation (deconsolidation) of sponsored investment funds (2,683) (1,639)
Issuance of Subco Units/common shares in connection with acquisitions 0 8,715
Established contingent consideration liabilities in connection with acquisitions $ 0 $ 3,413